Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.50 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28751563 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL30731537 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL29655357 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL31626952 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL2486538 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL23930714 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL227644 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL19971880 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL22471650 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 | |
| SCHEMBL27642486 | 1.00 | PRKCA (0.50) | PRKCAGLS2FAAHPRKCDGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4585893-A | Process for producing 4-homoisotwistane-3-carboxylic acid | KAO CORPORATION (JP) | 1986-04-29 | — | — | US | claimed |
| US-11891642-B2 | Biocatalytic techniques | HYPHA DISCOVERY LIMITED (GB) | 2024-02-06 | — | — | US | disclosed |
| CN-111527090-B | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220025416-A1 | BIOCATALYTIC TECHNIQUES | HYPHA DISCOVERY LIMITED (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3887512-A2 | BIOCATALYTIC TECHNIQUES | Hypha Discovery Ltd. (GB) | 2021-10-06 | — | — | EP | disclosed |
| CN-111527090-A | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020109776-A2 | BIOCATALYTIC TECHNIQUES | HYPHA DISCOVERY LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
| CN-110650738-A | Compounds and methods for treating parasitic diseases | 博德研究所 | 2020-01-03 | — | — | CN | disclosed |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170191985-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-07-06 | — | — | US | disclosed |
| WO-2004027378-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1183252-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| US-6492406-B1 | PROTEIN KINASE C INHIBITORS; ANTIINFLAMMATORY AND IMMUNO-SUPPRESSIVE AGENTS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1183252-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071537-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
| US-5270334-A | 4-methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| US-5248790-A | Antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| US-4226903-A | PAPER, ARAMIDS, THERMOSETTING RESINS | GENERAL ELECTRIC COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4171969-A | Bis(aminomethyl)phosphinic acid | CIBA-GEIGY CORPORATION (US) | 1979-10-23 | — | — | US | disclosed |
| US-4163912-A | Electrical insulating sheet material and electric winding made therefrom | GENERAL ELECTRIC COMPANY (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | CYP3A7, CYP3A43, CYP3A5 | PRKCA 4476/4885GLS2 49/4885FAAH 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.